Russia ready for second stage of clinical trials of innovative Parkinson's disease drug
Russia plans to begin a second stage of clinical trials of an innovative drug for the treatment of Parkinson's disease and which was developed by scientists from Novosibirsk and Tomsk. According to scientists, this is the world’s first drug that can stop the development of the disease.
The drug was designed by scientists from the Novosibirsk Institute of Organic Chemistry of the Siberian Branch of the Russian Academy of Sciences and the Tomsk State Corporation "Innovative pharmacological developments" (IFAR).
According to analysts, generics produced by domestic manufacturers cannot provide high-level of efficiency and safety of therapies, while the supplies of original Western drugs to Russia is currently seriously complicated by sanctions.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze